Azora Therapeutics, Inc. is a biopharmaceutical company that develops therapies for immune-mediated inflammatory diseases. Its investigational oral drug, AT177, is being develop for inflammatory bowel diseases, with an initial focus on ulcerative colitis. The company was founded by Julie Saiki and Matthew Davidson which is headquartered in Los Angeles, CA.